PGR and neoplasm: Patients are stratified into risk groups basing on the clinicopathological features (tumor size, lymph node stage, metastasis) combined with classical molecular features, such as the expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2)3.